Ionis Development

Ionis Pharmaceuticals is a leader in RNA-targeted therapeutics, specifically pioneering the development of antisense oligonucleotide (ASO) technology. The company has built a vast pipeline of medicines designed to treat a variety of diseases, including rare conditions, cardiovascular disorders, and neurological diseases. Ionis has successfully brought several products to market, such as Spinraza for spinal muscular atrophy and Tegsedi for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Their business model leverages a powerful technology platform to drive internal drug discovery while maintaining extensive high-value partnerships with major pharmaceutical companies to co-develop and commercialize their candidates.